How Serious Is the Biosimilar Void?

Key Takeaways

• FDA draft cuts PK study requirements for biosimilars.
• Biosimilar void exists for mid‑volume and rare‑disease biologics.
• Patent expirations in next five years will increase demand.
• New entrants could alleviate high‑price biologic scarcity.
• Guidance may reduce development costs, speeding market entry.

Pulse Analysis

The U.S. Food and Drug Administration’s March 2026 draft guidance marks a notable shift in the regulatory landscape for biosimilars. By proposing the removal of certain pharmacokinetic (PK) studies—particularly those that compare a candidate biosimilar directly with a U.S.-licensed reference product—the agency aims to streamline development pipelines and lower manufacturing expenses. Industry observers see this as a response to longstanding concerns that extensive PK requirements inflate timelines and deter smaller players. If implemented, the guidance could accelerate the entry of cost‑competitive biologics, aligning the U.S. more closely with the European model where biosimilar uptake is higher.

Despite the regulatory easing, executives like Thomas Newcomer of Samsung Bioepis warn of a persistent ‘biosimilar void’ in the American market. The gap is most pronounced for biologics that sit outside the blockbuster tier—mid‑volume therapies and treatments for rare diseases—where commercial incentives have been weaker. As a wave of patents on high‑priced biologics expires over the next five years, these underserved segments risk remaining without affordable alternatives. Developers must weigh scientific complexity against limited market size, a calculus that has historically slowed entry for niche indications.

Closing the void carries significant business and patient‑care implications. Greater competition can drive down list prices, improve insurance formularies, and expand access for conditions that currently rely on expensive originators. For manufacturers, the new guidance reduces upfront investment, making it more viable to pursue biosimilars in lower‑volume niches. Investors are likely to monitor pipeline announcements closely, as successful launches could reshape revenue streams for both legacy biologic firms and emerging biosimilar players. Ultimately, a more robust biosimilar ecosystem could reinforce the U.S. healthcare system’s cost‑containment goals while fostering innovation.